E Estey

2.5k total citations
29 papers, 1.8k citations indexed

About

E Estey is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, E Estey has authored 29 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 12 papers in Molecular Biology and 9 papers in Oncology. Recurrent topics in E Estey's work include Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (7 papers) and Retinoids in leukemia and cellular processes (6 papers). E Estey is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Acute Lymphoblastic Leukemia research (7 papers) and Retinoids in leukemia and cellular processes (6 papers). E Estey collaborates with scholars based in United States, United Kingdom and Italy. E Estey's co-authors include Hagop M. Kantarjian, John Rex, Richard J. Ridge, Zekaver Odabaşı, Paul A. Ketchum, Gloria Mattiuzzi, Malcolm Finkelman, Luis Ostrosky‐Zeichner, Menek Goldstein and Mark J. Kupersmith and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

E Estey

28 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E Estey United States 15 814 777 425 422 265 29 1.8k
Robert Corringham United States 18 494 0.6× 451 0.6× 142 0.3× 312 0.7× 147 0.6× 35 1.9k
Danielle M. Carrick United States 23 467 0.6× 227 0.3× 76 0.2× 426 1.0× 90 0.3× 35 1.6k
Hiroaki Goto Japan 22 485 0.6× 634 0.8× 120 0.3× 108 0.3× 171 0.6× 157 1.7k
Andrea Ferreira‐Gonzalez United States 26 835 1.0× 239 0.3× 164 0.4× 673 1.6× 116 0.4× 87 2.3k
Andrea Finocchi Italy 24 505 0.6× 154 0.2× 156 0.4× 330 0.8× 120 0.5× 84 1.8k
Xiaofan Zhu China 23 778 1.0× 651 0.8× 43 0.1× 103 0.2× 167 0.6× 241 1.8k
M Kashimura Japan 19 246 0.3× 139 0.2× 71 0.2× 144 0.3× 138 0.5× 71 1.2k
Priscilla M.K. Poon Hong Kong 14 788 1.0× 320 0.4× 707 1.7× 94 0.2× 113 0.4× 29 2.5k
Nobuo Nara Japan 25 800 1.0× 824 1.1× 57 0.1× 37 0.1× 198 0.7× 121 1.8k
G Mathé France 18 285 0.4× 392 0.5× 49 0.1× 98 0.2× 114 0.4× 105 1.4k

Countries citing papers authored by E Estey

Since Specialization
Citations

This map shows the geographic impact of E Estey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Estey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Estey more than expected).

Fields of papers citing papers by E Estey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E Estey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Estey. The network helps show where E Estey may publish in the future.

Co-authorship network of co-authors of E Estey

This figure shows the co-authorship network connecting the top 25 collaborators of E Estey. A scholar is included among the top collaborators of E Estey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E Estey. E Estey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shen, Lanlan, Hagop M. Kantarjian, Yi Guo, et al.. (2009). DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology. 28(4). 605–613. 261 indexed citations
2.
Ravandi, Farhad, E Estey, Dan Jones, et al.. (2008). Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. Journal of Clinical Oncology. 27(4). 504–510. 270 indexed citations
3.
Silva, Leandro de Pádua, Marcos de Lima, Hagop M. Kantarjian, et al.. (2007). Outcome of Allogeneic Stem Cell Transplantation after Hypomethylating Therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.. Blood. 110(11). 1468–1468. 5 indexed citations
4.
Aribi, Ahmed, Carlos E. Bueso‐Ramos, E Estey, et al.. (2007). Biphenotypic acute leukaemia: a case series. British Journal of Haematology. 138(2). 213–216. 40 indexed citations
5.
Faderl, Stefan, Farhad Ravandi‐Kashani, Alessandra Ferrajoli, et al.. (2005). Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) ≥ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML). Journal of Clinical Oncology. 23(16_suppl). 6627–6627. 3 indexed citations
6.
Odabaşı, Zekaver, Gloria Mattiuzzi, E Estey, et al.. (2004).  -D-Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Clinical Infectious Diseases. 39(2). 199–205. 477 indexed citations
7.
Jilani, Iman, et al.. (2002). Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia. Leukemia Research. 26(10). 899–902. 9 indexed citations
8.
Beran, Miloslav, et al.. (2001). Phase I study of prolonged administration of oral topotecan in hematological malignancies. 98. 3 indexed citations
9.
Appelbaum, Frederick R., MR Baer, Matthew Carabasi, et al.. (2000). NCCN Practice Guidelines for Acute Myelogenous Leukemia.. PubMed. 14(11A). 53–61. 25 indexed citations
10.
Vey, Norbert, Hagop M. Kantarjian, Hai T. Tran, et al.. (1999). Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Annals of Oncology. 10(5). 577–584. 18 indexed citations
11.
Andreeff, M., Shi Xue Hu, Hong-Ji Xu, et al.. (1998). Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study.. PubMed. 4(8). 1955–63. 15 indexed citations
12.
Estey, E, Marcos de Lima, Sara S. Strom, et al.. (1997). Long‐term follow‐up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center. Cancer. 80(S11). 2176–2180. 4 indexed citations
13.
Estey, E, Peter F. Thall, Gareth Pierce, H Kantarjian, & Michael J. Keating. (1997). Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.. Journal of Clinical Oncology. 15(2). 483–490. 101 indexed citations
14.
Kurzrock, Razelle, E Estey, S O'Brien, et al.. (1997). Second cancer risk in hairy cell leukemia: analysis of 350 patients.. Journal of Clinical Oncology. 15(5). 1803–1810. 92 indexed citations
15.
Dimopoulos, Meletios Α., H. Kantarjian, D. Weber, et al.. (1994). Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine.. Journal of Clinical Oncology. 12(12). 2694–2698. 95 indexed citations
16.
Estrov, Zeev, Razelle Kurzrock, E Estey, et al.. (1992). Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors. Blood. 79(8). 1938–1945. 6 indexed citations
17.
18.
19.
Plunkett, William, et al.. (1990). Pharmacologically directed design of aml therapy. 1397346260. 1 indexed citations
20.
Lieberman, Abraham, Mark J. Kupersmith, Govindan Gopinathan, et al.. (1979). Bromocriptine in Parkinson disease. Neurology. 29(3). 363–363. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert Corringham Breakdown of academic impact, for papers by Danielle M. Carrick Breakdown of academic impact, for papers by Hiroaki Goto Breakdown of academic impact, for papers by Andrea Ferreira‐Gonzalez Breakdown of academic impact, for papers by Andrea Finocchi Breakdown of academic impact, for papers by Xiaofan Zhu Breakdown of academic impact, for papers by M Kashimura Breakdown of academic impact, for papers by Priscilla M.K. Poon Breakdown of academic impact, for papers by Nobuo Nara Breakdown of academic impact, for papers by G Mathé
Rankless by CCL
2026